BCRX Share Price Performance
US$9.16
1.53 (20.05%)
57.0% undervalued intrinsic discount
US$21.30
Fair Value
Price US$9.16
AnalystConsensusTarget US$21.30
AnalystLowTarget US$13.00
AnalystHighTarget US$32.00
Fair ValueUS$21.30
Share Pricen/a
BioCryst Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 40 Fair Values set on narratives written by author
BCRX Community Narratives
AN
Fair Value US$21.3 57.0% undervalued intrinsic discount
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
0users have liked this narrative
1users have commented on this narrative
21users have followed this narrative
AN
Fair Value US$13 29.5% undervalued intrinsic discount
Rare Disease Focus Will Face Intense Rivalry Yet Value Persists
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$32 71.4% undervalued intrinsic discount
Orladeyo Expansion And Genomics Advances Will Reshape Global Markets
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Key Takeaways Sustained revenue and profit growth are driven by successful ORLADEYO performance, new indications, and broader rare disease market expansion. Enhanced financial flexibility and a strong pipeline position BioCryst for strategic growth through M&A, new product launches, and operational leverage.Read more
419
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
21users have followed this narrative
AN
US$21.3
57.0% undervalued intrinsic discount
Fair Value
Revenue
0.95% p.a.
Profit Margin
10.11%
Future PE
89.13x
Price in 2029
US$26.41
Orladeyo Expansion And Genomics Advances Will Reshape Global Markets
Key Takeaways Surging ORLADEYO adoption and swift expansion into new indications suggest greater and faster recurring revenue than forecasts, with strong support from prescribers, payors, and real-world results. Robust pipeline, acquisition ambition, and expanding global rare disease demand position BioCryst for durable, diversified, high-margin growth beyond current market expectations.Read more
62
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$32
71.4% undervalued intrinsic discount
Fair Value
Profit Margin
30.23%
Future PE
29.33x
Price in 2029
US$39.89
Rare Disease Focus Will Face Intense Rivalry Yet Value Persists
Key Takeaways Heavy reliance on a single product exposes BioCryst to risks from competition, regulatory shifts, and a limited pipeline in the rare disease market. Expanding demand for innovative rare disease therapies could be offset by rising pricing pressures, regulatory hurdles, and competition from larger and emerging market players.Read more
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13
29.5% undervalued intrinsic discount
Fair Value
Profit Margin
8.44%
Future PE
49.89x
Price in 2029
US$16.28
Trending Discussion
Recently Updated Narratives
AN
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Fair Value: US$21.3 57.0% undervalued intrinsic discount
21 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Fair Value: US$32 71.4% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Fair Value: US$13 29.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioCryst Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 1.05
- 79.32%
- 30.16%
- -390.8%
About BCRX
- Founded
- 1986
- Employees
- 435
- CEO
- WebsiteView website
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
